Expertise in
53
conditions

Dr. David J. Park

Hematology Oncology
2151 North Harbor Boulevard, Suite 2100, 
Fullerton, CA 
Accepting New Patients
Offers Telehealth
Referral may be required
Expertise in
53
conditions
2151 North Harbor Boulevard, Suite 2100, 
Fullerton, CA 

Overview

David Park is a Hematologist Oncology provider practicing medicine in Fullerton, California.

Dr. Park is highly rated in 53 conditions, according to our data. His clinical expertise encompasses Small Cell Lung Cancer (SCLC), Non-Hodgkin Lymphoma, Lung Cancer, and Neuroendocrine Tumor.

He is actively involved in clinical research, co-authoring 6 peer reviewed articles and participating in 11 clinical trials. Dr. Park is currently accepting new patients.

Specialties

Hematology Oncology

Licenses

Internal Medicine in CA

Hospital Affiliations

Providence St. Jude Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
Silversummit Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

2151 North Harbor Boulevard, Suite 2100, Fullerton, CA 92835

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure
LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure
Enrollment Status: Completed
Publish Date: March 18, 2026
Intervention Type: Drug, Device
Study Drug: Immune checkpoint inhibitors or docetaxel
Study Phase: Phase 3
A Phase 2b/3, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)
A Phase 2b/3, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)
Enrollment Status: Completed
Publish Date: October 15, 2025
Intervention Type: Drug
Study Drug: Leronlimab
Study Phase: Phase 2
A Phase 1, Open-Label, Dose Escalation of HBI-2376 in Patients With Advanced Malignant Solid Tumors Harboring KRAS or EGFR Mutations
A Phase 1, Open-Label, Dose Escalation of HBI-2376 in Patients With Advanced Malignant Solid Tumors Harboring KRAS or EGFR Mutations
Enrollment Status: Active_not_recruiting
Publish Date: September 24, 2025
Intervention Type: Drug
Study Drug: HBI-2376
Study Phase: Phase 1
St. Judes-Stanford Comprehensive Support Initiative
St. Judes-Stanford Comprehensive Support Initiative
Enrollment Status: Completed
Publish Date: January 24, 2025
Intervention Type: Procedure, Other
Study Phase: Not Applicable
A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
Inhaled ZYESAMI™ for the Treatment of Severe COVID-19
Inhaled ZYESAMI™ for the Treatment of Severe COVID-19
Enrollment Status: Terminated
Publish Date: February 03, 2023
Intervention Type: Drug, Device
Study Drug: ZYESAMI™
Study Phase: Phase 2/Phase 3
A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer
A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: June 28, 2022
Intervention Type: Drug
Study Drugs: Olaratumab, Nab-paclitaxel, Gemcitabine
Study Phase: Phase 1/Phase 2
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
Enrollment Status: Terminated
Publish Date: July 30, 2021
Intervention Type: Drug
Study Drugs: Tesetaxel and Capecitabine, Capecitabine
Study Phase: Phase 3
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Enrollment Status: Completed
Publish Date: October 19, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine Versus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine Versus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: September 18, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

6 Total Publications

Where will I end up? Relative location of sports medicine fellowship compared to residency among recent graduates.
Where will I end up? Relative location of sports medicine fellowship compared to residency among recent graduates.
Journal: BMC medical education
Published: November 17, 2025
Similar Doctors
Expertise in
16
conditions
Dr. Yung Lyou
Hematology Oncology | Oncology
Expertise in
16
conditions
Dr. Yung Lyou
Hematology Oncology | Oncology
2151 North Harbor Boulevard, Suite 2100, 
Fullerton, CA 
 (9.8 miles away)
714-446-5900
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Yung Lyou is a Hematologist Oncology specialist and an Oncologist practicing medicine in Fullerton, California. Dr. Lyou is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Renal Cell Carcinoma (RCC), Familial Prostate Cancer, Chromophobe Renal Cell Carcinoma, and Hormone Replacement Therapy (HRT). Dr. Lyou is currently accepting new patients.

Expertise in
42
conditions
Dr. Steven W. Kim
Hematology Oncology
Expertise in
42
conditions
Dr. Steven W. Kim
Hematology Oncology
15855 Pomona Rincon Road, 
Chino Hills, CA 
 (6.8 miles away)
714-446-5900
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Steven Kim is a Hematologist Oncology provider practicing medicine in Chino Hills, California. Dr. Kim is highly rated in 42 conditions, according to our data. His clinical expertise encompasses Paris-Trousseau Thrombocytopenia, RUNX1 Familial Platelet Disorder, Anemia, Schnitzler Syndrome, and Bone Marrow Aspiration. Dr. Kim is currently accepting new patients.

Expertise in
39
conditions
Dr. Sanjay Sharma
Hematology Oncology
Expertise in
39
conditions
Dr. Sanjay Sharma
Hematology Oncology
2151 North Harbor Boulevard, Suite 2100, 
Fullerton, CA 
 (9.8 miles away)
714-446-5900
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sanjay Sharma is a Hematologist Oncology provider practicing medicine in Fullerton, California. Dr. Sharma is highly rated in 39 conditions, according to our data. His clinical expertise encompasses Paget Disease of the Breast, Inflammatory Breast Cancer, Angiosarcoma, and Clear Cell Sarcoma. Dr. Sharma is currently accepting new patients.

Frequently Asked Questions about Dr. David J. Park

How do I make an appointment with Dr. David J. Park?

You can book an appointment with Dr. David J. Park by calling their office at 714-446-5900. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. David J. Park a top-rated expert for Small Cell Lung Cancer (SCLC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. David J. Park is classified as an Distinguished expert for Small Cell Lung Cancer (SCLC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. David J. Park specialize in?

While Dr. David J. Park is a Hematology Oncology, they have specific expertise in Small Cell Lung Cancer (SCLC), Non-Hodgkin Lymphoma, and Lung Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.

Does Dr. David J. Park participate in research or clinical trials?

Yes. Dr. David J. Park has published 6 articles and abstracts on conditions like Small Cell Lung Cancer (SCLC). You can view a list of Dr. David J. Park's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. David J. Park accept my insurance?

Dr. David J. Park accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 714-446-5900 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Park's expertise for a condition
ConditionClose
    View All 18 Distinguished Conditions
    View All 35 Advanced Conditions
    View All 112 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile